 |
市場調查報告書
商品編碼
1812612
美國的醫藥品的藥價設定與給付:資料為基礎分析Pricing and Reimbursement of Pharmaceuticals in the US: A Data-Driven Analysis |
||||||
本報告對美國藥品定價與報銷進行了深入的數據驅動分析，重點關注聯邦醫療保險 (Medicare) D 部分和醫療補助 (Medicaid)。報告利用 2011 年至 2023 年的支出、處方和理賠數據，檢視了這兩個系統的趨勢，並詳細回顧了 2023 年聯邦醫療保險 D 部分報銷排名前 50 位的品牌藥品。
深入了解支出模式、處方量和理賠指標的波動、聯邦醫療保險 (Medicare) 和醫療補助 (Medicaid) 報銷的差異，以及近期政策變化（例如《降低通貨膨脹法案》和 2025 年行政命令）對高價藥品定價和談判的影響。
關鍵問題
- 1. Medicare D 部分和 Medicaid 藥品定價和報銷的當前趨勢。
- 2.包括《通貨膨脹削減法案》和 2025 年行政命令在內的近期政策如何影響高價藥品的定價和報銷？
- 3.2023 年 Medicare D 部分報銷前 50 名的藥品的支出模式。
- 4.前 50 名的藥品的處方量和申請人指標有何變化？
- 5.Medicare D 部分和 Medicaid 藥品報銷之間的主要區別是什麼？
- 6.不同藥品和治療領域的每張處方支出和每位申請人的支出如何比較？
- 7.製造商返利和價格優惠如何影響支出資料的解讀？
- 8.透過即將到來的醫療保險藥品價格談判，預計美國藥品定價和報銷將出現哪些趨勢？
主要企業
|
|
|
調查手法
本報告是基於獨立而簡潔的分析，這些分析源自於專有的產業研究以及對產業意見領袖的深入訪談。報告深入分析了製藥企業高管需要了解的關鍵發展和市場趨勢，以應對未來的機會和課題。每份報告的重點都基於對二手文獻的回顧和已發現的知識缺口。基於這項初步研究，我們制定了基於證據的討論指南，並融入專家意見，以確保研究能夠解答最重要的問題。此外，我們採用嚴格的篩選標準，以確保受訪者擁有就該主題發言的經驗、知識和資格。
我們報告的特點
FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供深入、可操作的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助我們的客戶掌握新興趨勢，並有效應對複雜的課題。憑藉廣泛的研究以及來自頂尖專家和關鍵意見領袖的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家訪問獨家訪談和數據，以及持續的市場監測，確保全面了解市場動態。我們的報告涵蓋 40 多個動態疾病領域、包括 KOL 洞察和定量醫生調查在內的醫生情報以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入和其他領域問題的看法，使您能夠做出更明智的、數據驅動的決策，並在快速變化的行業中保持競爭力。
This report provides a detailed, data-driven analysis of pharmaceutical pricing and reimbursement in the US, focusing on Medicare Part D and Medicaid. Drawing on 2011-2023 expenditure, prescription and claimant data, it examines trends across both programs and offers an in-depth review of the top 50 branded drugs reimbursed under Medicare Part D in 2023.
Gain insight into expenditure patterns, variations in prescription volumes and claimant metrics, differences between Medicare and Medicaid reimbursement and the implications of recent policy developments, including the Inflation Reduction Act and the 2025 Executive Order, on high-cost drug pricing and negotiation.
Key Questions Answered:
- 1. What are the current trends in pharmaceutical pricing and reimbursement under Medicare Part D and Medicaid?
- 2. How has recent policy, including the Inflation Reduction Act and 2025 Executive Order, impacted high-cost drug pricing and reimbursement?
- 3. What are the expenditure patterns for the top 50 drugs reimbursed through Medicare Part D in 2023?
- 4. How do prescription volumes and claimant metrics vary among these top 50 drugs?
- 5. What are the key differences in drug reimbursement between Medicare Part D and Medicaid?
- 6. How do expenditure per prescription and per claimant compare across drugs and therapy areas?
- 7. How do manufacturer rebates and price concessions factor into the interpretation of expenditure data?
- 8. What are the projected trends in US pharmaceutical pricing and reimbursement through upcoming Medicare drug price negotiations?
Key Companies:
|
|
|
Methodology:
Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
全球藥房配藥市場規模（按配藥類型、治療領域、應用和地區分類）預測
通訊藥品市場：按產品類型、按藥品類型、按治療領域、按類型、按服務模式、按最終用戶、按地區
複合藥房市場； - 2024 年至 2034 年全球產業分析、規模、佔有率、成長、趨勢和預測按產品類型、治療領域、應用和地區分類的配藥市場
複合藥房市場規模、佔有率和成長分析（按治療領域、年齡層、類型、不孕性別和地區）- 行業預測 2025-2032
美國複合藥房市場規模、佔有率和趨勢分析報告：按類型、治療領域、年齡層、複合類型、無菌性別、細分市場預測，2024-2030複合藥局市場 - 分產品（口服、腸胃外、局部、眼科、鼻腔、直腸、耳科）治療領域（疼痛管理、荷爾蒙替代）、應用、複合類型、無菌、配銷通路、全球預測 2024 - 2032複合藥房市場 - 全球行業規模、佔有率、趨勢、機會和預測，按治療領域、給藥途徑、最終用戶（按地區和競爭）細分，2019-2029F
美國郵購藥品市場規模和預測、國家和佔有率、趨勢和成長機會分析覆蓋範圍：藥物類型、產品和訂購方式